Olysio® gains additional FDA approval as all-oral

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Olysio® gains additional FDA approval as all-oral treatment in combination with sofosbuvir for treatment of hepatitis C infection

-Expanded indication includes both treatment-naïve and treatment-experienced adult patients with or without cirrhosis- Stockholm, Sweden – Medivir AB (Nasdaq Stockholm:MVIR) announces that the U.S. Food and Drug Administration (FDA) has approved Olysio® (simeprevir) in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C infection in adult patients as part of a combination antiviral treatment regimen. The sNDA was filed in May by Medivir’s partner Janssen Research & Development LLC. Data supporting the Olysio® and sofosbuvir combination regimen are from the COSMOS study, an open-label, randomized phase II clinical trial that investigated the efficacy and safety of 12 or 24 weeks of Olysio® (150 mg once daily) in combination with sofosbuvir (400 mg once daily), with or without ribavirin in HCV genotype 1 chronically infected naïve and treatment-experienced adult patients with compensated liver disease. The recommended treatment duration of Olysio® with sofosbuvir is 12 weeks for patients without cirrhosis or 24 weeks for patients with cirrhosis. The COSMOS study In the COSMOS study 95 percent of patients (20/21) with METAVIR F0-F3 (patients with no liver fibrosis to near cirrhotic liver disease) receiving 12 weeks of Olysio® with sofosbuvir achieved SVR12 (sustained virologic response 12 weeks after the end of treatment). Regardless of whether patients were treatment-naïve or treatment-experienced 86 percent of patients (6/7) with METAVIR F4 (cirrhosis) receiving 12 weeks of Olysio® in combination with sofosbuvir achieved SVR12, while 100 percent (10/10) of patients with cirrhosis who were treated with the combination for 24 weeks achieved SVR12. For all patients in the COSMOS trial (treatment-naïve and treatment-experienced, METAVIR F0-F4), 93 percent (26/28) achieved SVR12 after 12 weeks and 97 percent (30/31) achieved SVR12 after 24 weeks of treatment. In the COSMOS trial, the most common (> 10 percent) adverse reactions reported during 12 weeks of treatment with Olysio® in combination with sofosbuvir without ribavirin were fatigue (25 percent), headache (21 percent), nausea (21 percent), insomnia (14 percent) and pruritus (11 percent). Rash and photosensitivity were reported in 11 percent and 7 percent of patients, respectively. During 24 weeks of treatment, dizziness (16 percent), and diarrhea (16 percent) were also reported. Janssen has a robust HCV clinical development program, including phase II and III studies combining Olysio® with other direct acting antivirals. For more information please visit www.clinicaltrials.gov. For further information, please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292. Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 8.30 CET on 6 November 2014. About Simeprevir (Olysio®) Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis. Simeprevir was approved in September 2013 in Japan, in November 2013 in Canada and the U.S., in March 2014 in Russia and in July 2014 in Mexico and Australia. In May 2014 simeprevir was granted marketing authorization by the European Commission (EC) for the treatment of adult patients with genotype 1 or genotype 4 chronic HCV. Following the EMA approval, it has so far been made available in several EU countries in conjunction with reimbursement. Simeprevir (Olysio) is marketed under the trade name Sovriad® in Japan and Russia, Galexos™ in Canada and Olysio® in the U.S. and European Union. About Medivir Medivir is an emerging and profitable research‐based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals. Medivir receives royalties from Johnson & Johnson on the global sales of the hepatitis C pharmaceutical, Olysio®. In addition, revenues for sales of Olysio in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science. The company’s research and development focus is within infectious diseases and oncology and the on-going clinical projects in osteoarthritis and neuropathic pain. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 301

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Haemonetics Opens Europe for VASCADE MVP XL Device

Updated Category News Views 81

A larger collagen plug is hardly cocktail-party material, yet it can matter a great deal when it sits inside a procedure workflow hospitals are trying to speed up. Haemonetics has received CE Mark certification under the EU Medical Device Regulation for VASCADE MVP XL, its larger-bore venous vascular closure system, and first commercial European procedures were completed...

Continue Reading
Photocure Opens a New Access Route for Hexvix Patients

Updated Category News Views 78

Forty-plus markets just moved from “not available” toward a workable route for individual bladder cancer patients, and that is the real substance of Photocure’s new arrangement with Clinigen. This is not a sweeping product launch, nor is it an approval announcement dressed up in confetti. It is a Named Patient Program, which matters because the regulatory plumbing...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 116

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 267

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 229

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 34

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 248

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 0

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading

Top 5 Most Recently Viewed Articles

EHang's Progress and Financial Results: Navigating Change

Updated Category News Views 389

EHang Reports Its Third Quarter Financial Performance EHang Holdings Limited (NASDAQ: EH), a leader in advanced air mobility, has recently released its unaudited financial results for the third quarter. The company continues to strive towards maintaining its full-year revenue guidance of RMB500 million. In this article, we will highlight key operational and financial...

Continue Reading
Analysts Revise Procter & Gamble Earnings Forecasts Ahead of Q1 Results

Updated Category News Views 107

Procter & Gamble Earnings Forecast The Procter & Gamble Company (NYSE: PG) is on the verge of releasing its first-quarter earnings results. Analysts have been busy revising their forecasts ahead of this pivotal moment for the company. Expectations Leading to Earnings Analysts predict that Procter & Gamble will report quarterly earnings of $1.90 per share, marking an...

Continue Reading
BLM Engages Advocates in Revolutionary Wild Horse Dialogue

Updated Category News Views 244

BLM Partners with Advocates for Wild Horse Management The Bureau of Land Management (BLM) has taken a significant step by inviting a group of citizen advocates to work together on the management of wild horses and burros. This initiative marks an important moment in wild horse conservation, providing a unique opportunity for open conversation between the BLM and...

Continue Reading
Covenant Logistics Announces New Quarterly Cash Dividend Details

Updated Category News Views 137

Covenant Logistics Declares Quarterly Cash Dividend Covenant Logistics Group, Inc. has officially announced a quarterly cash dividend of $0.07 per share, benefiting both Class A and Class B common stockholders. This dividend decision, made by the Company’s board of directors, demonstrates their commitment to returning value to shareholders and reflects the company's...

Continue Reading
Landsbankinn hf. Prepares for Upcoming Q3 2024 Financial Release

Updated Category News Views 57

Landsbankinn hf. Announces Financial Results Release Date Landsbankinn hf. is gearing up to share its financial outcomes for the third quarter of 2024. This important event is scheduled for a Wednesday, and stakeholders are keenly anticipating the insights this release will bring. What to Expect from the Financial Results Investors are always on the lookout for key...

Continue Reading